Abstract
Background: Cryptococcal meningitis (CM) is a severe fungal infection caused primarily by Cryptococcus neoformans and less commonly by Cryptococcus gattii. It poses a significant threat to individuals with compromised immune systems, particularly those living with Human Immunodeficiency Virus (HIV). Despite advancements in antiretroviral therapy (ART), CM remains a leading cause of mortality among HIV-infected individuals, especially in low- and middle-income countries.
Aim: This study was done to determine the prevalence of Cryptococcus among HIV-infected patients attending at Central University Hospital of Kigali, Rwanda and the level at which a patient’s CD4 count is significantly associated with cryptococcal meningitis.
Methodology: A retrospective study was conducted at Central University Hospital of Kigali, Rwanda. This study included 60 HIV-infected patients whose serum and CSF samples were examined for Cryptococcus by one of or all 4 tests (CSF culture, CSF CrAg, serum CrAg and Indian Ink) and their results were recorded.
Results: Among the 60 HIV-infected patients enrolled, 8 (13%) were positive for cryptococcal meningitis. Among these 8 patients the CD4 count ranged from 2-200 cells/ul, and 31.82% (7 of 8) was among patients with CD4 count ≤100 c/ul and 6.25% (1 of 8) was among patients with CD4 count levels between 101 c/ul and 200c/ul. Based on the study results, CD4 count levels lower or equal to 100 cells/ul was highly associated with cryptococcal meningitis as the P-value=0.001 and Odd ratio=0.058.
Conclusion: Based on the study results there was a significant association between cryptococcal meningitis and lower CD4 count levels. HIV-infected patients with CD4 counts ≤100 cells had the highest prevalence. Therefore, the level of CD4 count below or equal to 100 cells/ul is highly associated with positive cryptococcal meningitis. However, there were cases of positive CM among HIV patients with CD4 count ≥100 cells/ul.
Keywords: Cryptococcal meningitis, CD4 count, HIV,
Publisher
Society of Pharmaceutical Tecnocrats
Reference16 articles.
1. 1. Rajasingham, R., et al. Global burden of disease of HIV-associated cryptococcal meningitis: an updated analysis. The Lancet Infectious Diseases; 2017;17(8):873-881. https://doi.org/10.1016/S1473-3099(17)30243-8 PMid:28483415
2. 2. Tenforde, M. W., et al. Mortality from HIV-associated cryptococcal meningitis in Africa: a systematic review and meta-analysis. The Lancet Infectious Diseases;2020;20(8):955-963.
3. 3. Meya, D. B., & Muzoora, C. Overview of the management of cryptococcal meningitis in sub-Saharan Africa. Therapeutic Advances in Infectious Disease;2020;7:2049936120916014.
4. 4. Boulware, D. R., et al. Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. The New England Journal of Medicine;2020;382(26):2497-2508.
5. 5. Rothe, C., et al. Emergence of antifungal resistance in Cryptococcus species: current challenges and future directions. Mycoses;2021;64(11):1312-1322.